Transaction in the Exosome filed
JUNE 2020 STAGE: PRE-CLINICAL
Eli Lilly and Evox $1.2 billion collaboration to apply exosome technology to delivering RNA interference and antisense oligonucleotide drugs, to reach central nervous system targets.
Evox received $20 million upfront and eligible to receive up to $1.2 billion in direct investment, milestones & royalties.
MARCH 2020 STAGE: PRE-CLINICAL
Takeda and Evox collaboration to utilize Evox’s exosome technology to develop candidates for rare brain-related diseases
Evox received $44M upfront and eligible to receive up to $838M in milestones & royalties.
JANUARY 2019 STAGE: PRE-CLINICAL
Jazz licensed Codiak Biosciences’ exosome technology to develop up to 5 cancer candidates.
Codiak received $56M upfront and eligible to receive up to $20M in pre-clinical milestones, up to US$200M in milestones for each of the 5 candidates, plus royalties.
JULY 2018 STAGE: PRE-CLINICAL
Roche licensed PureTech’s exosome technology to develop oral antisense candidates.
PureTech received $36M upfront eligible to receive over $1 billion in milestones and royalties.